The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | QoL of patients with newly diagnosed myeloma receiving elotuzumab plus RVd in a Phase III trial
In this video, Anna Fleischer, MD, University Hospital Würzburg, Würzburg, Germany, briefly comments on the quality of life (QoL) outcomes in patients with newly diagnosed multiple myeloma (MM) treated with a combination of elotuzumab plus lenalidomide, bortezomib, and dexamethasone (RVd) in the Phase III GMMG-HD6 trial (NCT02495922). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
